European Myeloma Network   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Aalborg Denmark (2005)

Organization Overview

First Clinical Trial
2006
NCT00832234
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

EMN Research Italy | EMN Research Italy Impresa Sociale Srl | European Myeloma Network

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyloidosis (Phase 3)

Immunoglobulin Light-chain Amyloidosis (Phase 3)

Multiple Myeloma (Phase 3)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Plasmacytoma (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 21